GLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm

On August 8, 2022, GBT announced that it had entered into an agreement to be acquired by Pfizer in an all-cash deal with an enterprise value of $5.4 billion.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, August 9, 2022

Information

Tags:

P.C, Telephone, NYSE, GLOBE, GBT, Learning, PFE, Pfizer, Acquisition, NASDAQ, Squire, Pharmaceutical industry, Property management

Geotags:

NEW YORK, NY, US, CALIFORNIA, SOUTH CAROLINA

Organisation:

BRAGAR EAGEL & SQUIRE

Stock Symbol:

NASDAQ:GBT

NYSE:PFE

Summary

Key Points:

On August 8, 2022, GBT announced that it had entered into an agreement to be acquired by Pfizer in an all-cash deal with an enterprise value of $5.4 billion.
Pursuant to the merger agreement, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash.
Bragar Eagel & Squire is concerned that GBTs board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Global Blood Therapeutics, Inc. (NASDAQ: GBT) (“GBT”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Pfizer Inc. (NYSE: PFE) (“Pfizer”).

Click here to learn more and participate in the action.

On August 8, 2022, GBT announced that it had entered into an agreement to be acquired by Pfizer in an all-cash deal with an enterprise value of $5.4 billion. Pursuant to the merger agreement, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash. The deal is scheduled to close as early as the fourth quarter of 2022.

Bragar Eagel & Squire is concerned that GBT’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for GBT’s stockholders.

If you own shares of GBT and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato by email at [email protected] or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
[email protected]
www.bespc.com